Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunome (IMNM) has issued an update.
Bob Lapetina is set to depart from his executive roles at Immunome, Inc. on May 10, 2024, to explore new opportunities, leaving behind no company disputes. Following his exit, Max Rosett will step up as the new principal accounting officer. Bringing a diverse background, including a tenure at Morphimmune, Inc. and experience at Google and the Boston Consulting Group, Rosett’s appointment consolidates his financial leadership within Immunome, underlined by his recent role as Interim CFO and EVP of Operations. This strategic shift in the financial department signals continuous evolution in the company’s executive suite.
Learn more about IMNM stock on TipRanks’ Stock Analysis page.